Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.51 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3179202 | 0.98 | LMNA (0.63) | LMNAPTGS2PTGS1MAPK14MAPK13 | |
| SCHEMBL14687973 | 0.89 | LMNA (0.50) | LMNAPTGS2PTGS1MAPK14MAPK13 | |
| SCHEMBL1010895 | 0.88 | LMNA (0.61) | LMNAPTGS2PTGS1MAPK14MAPK13 | |
| SCHEMBL2461984 | 0.86 | PTGS2 (0.68) | LMNAPTGS2PTGS1NPY5RCYP1A2 | |
| SCHEMBL29396795 | 0.85 | MAPK14 (0.54) | LMNAPTGS2PTGS1MAPK14MAPK13 | |
| SCHEMBL2081538 | 0.85 | MAPK14 (0.54) | LMNAPTGS2PTGS1MAPK14MAPK13 | |
| Hydrochloric Acid SCHEMBL1410273 | 0.84 | MAPK14 (0.53) | LMNAPTGS2PTGS1MAPK14MAPK13 | |
| SCHEMBL20396179 | 0.84 | MEN1 (0.50) | LMNAPTGS2PTGS1CYP1A2CYP3A4 | |
| SCHEMBL14701816 | 0.84 | LMNA (0.49) | LMNAPTGS2PTGS1MAPK14MAPK13 | |
| SCHEMBL2571745 | 0.84 | MAPT (0.55) | LMNAPTGS2PTGS1MAPK14MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | claimed |
| US-20100029626-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | claimed |
| EP-1670787-A4 | CYTOKINE INHIBITORS | KEMIA INC (US) | 2009-04-22 | — | — | EP | claimed |
| EP-1996558-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | claimed |
| WO-2007104538-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2007-09-20 | — | — | WO | claimed |
| EP-1670787-A2 | CYTOKINE INHIBITORS | Kemia, INC. (US) | 2006-06-21 | — | — | EP | claimed |
| US-20050107399-A1 | Cytokine inhibitors | KEMIA, INC. | 2005-05-19 | — | — | US | claimed |
| WO-2005023761-A2 | CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2005-03-17 | — | — | WO | claimed |
| WO-2025067411-A1 | NEK7 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京普祺医药科技股份有限公司 | 2025-04-03 | — | — | WO | disclosed |
| CN-119060018-A | N, N-diaryl urea derivative and application thereof | 杭州百新生物医药科技有限公司 | 2024-12-03 | — | — | CN | disclosed |
| EP-3999057-A1 | POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES | ANAGENESIS BIOTECHNOLOGIES SAS (FR) | 2022-05-25 | — | — | EP | disclosed |
| CN-114144410-A | Polyarylurea derivatives and their use in the treatment of muscular diseases | 阿纳格纳斯生物技术股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
| US-10813932-B2 | 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors | RESPIVERT LIMITED (GB) | 2020-10-27 | — | — | US | disclosed |
| US-10358445-B2 | Respiratory formulations and compounds for use therein | Respivert, Ltd. (GB) | 2019-07-23 | — | — | US | disclosed |
| WO-2005023761-A2 | CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20040180906-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2004-09-16 | — | — | US | disclosed |
| US-20040171075-A1 | Modulation of protein functionalities | DECIPHERA PHARMACEUTICALS, LLC | 2004-09-02 | — | — | US | disclosed |
| WO-2004061084-A2 | MODULATION OF PROTEIN FUNCTIONALITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060306-A2 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2004-07-22 | — | — | WO | disclosed |
| CN-1283192-A | Inhibition of raf kinase using aryl and hetroaryl substituted heterocyclic ureas | BAYER AG (US) | 2001-02-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029626-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | SLC8B1, MCU, GLS | LMNA 2752/4885PTGS2 1092/4885PTGS1 681/4885 |
| US-20050107399-A1 | Cytokine inhibitors | TNF, IL1RN, IL1A | LMNA 4640/4885PTGS2 127/4885PTGS1 63/4885 |
| US-10358445-B2 | Respiratory formulations and compounds for use therein | TSLP, CCL11, RORB | LMNA 2963/4885PTGS2 354/4885PTGS1 84/4885 |
| US-10813932-B2 | 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors | MAPK1, MAP3K1, MAP3K8 | LMNA 3360/4885PTGS2 121/4885PTGS1 65/4885 |
| US-20040180906-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | LMNA 3791/4885PTGS2 16/4885PTGS1 12/4885 |
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | MAP3K20, PHKG1, PHKG2 | LMNA 2458/4885PTGS2 1845/4885PTGS1 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.